- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 03.09. | Wave RNA editing restores enzyme in genetic condition but underwhelms investors | ||
| 03.09. | FDA proposal would allow single-arm trials as confirmatory evidence for ultra-rare diseases | ||
| 03.09. | Treeline reaps $200M series A extension, plucks first 3 clinical candidates | ||
| 03.09. | Pfizer, Valneva boosted by updated vaccine data ahead of moment in the Lyme-light | ||
| 03.09. | Novartis returns to Argo for multifaceted $5B cardiovascular collab | ||
| 02.09. | Servier shells out $210M upfront to license Ideaya's potential first-in-class PKC inhibitor outside the US | ||
| 02.09. | Boston biotech Radiance offers China firm $1B-plus for rights to next-gen ADC | ||
| 02.09. | As Cytokinetics awaits FDA approval decision, phase 3 cardio win sends stock soaring | ||
| 02.09. | After strategic pivot, Editas lays out plan to target high cholesterol with gene editing | ||
| 02.09. | Amgen to build $600M R&D site, hire hundreds in California | ||
| 02.09. | Royalty bestows Zenas with $300M deal to push autoimmune asset across FDA finish line | ||
| 02.09. | Vertex forges $2B-plus alliance with Enlaza to create new autoimmune drugs, improve conditioning methods | ||
| 02.09. | Novartis takes another shot at alpha-synuclein with $2.2B Arrowhead CNS deal | ||
| 02.09. | Merck dives into regulatory talks after oral PCSK9 delivers 3rd phase 3 win | ||
| 02.09. | Zymeworks drops clinical-stage T-cell engager after assessing benefit-risk profile | ||
| 02.09. | Chasing pharma heavyweights, Upstream posts phase 2 sinusitis win but stock flows downhill | ||
| 02.09. | Lilly ends 2 of 3 midstage trials for oral GLP-1 contender naperiglipron | ||
| 01.09. | AstraZeneca gears up for FDA filing after sharing details of baxdrostat's hypertension success | ||
| 01.09. | Roche sees Alnylam hypertension RNAi drug flunk trial but still plans phase 3 push | ||
| 29.08. | Zydus' phase 3 liver disease win tees up filing to challenge Gilead and Ipsen | ||
| 29.08. | Fosun rises again, inking 3rd inflammatory disease deal in 3 weeks | ||
| 29.08. | BeOne's BCL2 drug hits primary endpoint, setting stage for filings to take up blood cancer mantle | ||
| 28.08. | Months after layoffs, AbbVie-partnered protein degrader specialist Plexium raises $60M | ||
| 28.08. | FDA considers noninvasive liver endpoint for clinical trials, sending MASH biotechs' shares up | ||
| 28.08. | Flagship taps IQVIA as biotech support for company fleet |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .